18 May 2013
Keywords: oxford, sanofi, trovax, renal, cancer, deal, uk-based
Article | 02 April 2007
UK-based biopharmaceutical group Oxford BioMedica and French drug major Sanofi-Aventis have entered into a global licensing agreement to develop
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 April 2007
17 May 2013
© 2013 thepharmaletter.com